• Explore /
  • Poster
  • / Phase I: Veliparib with cisplatin (CP) and vinorelbine (VNR) in advanced triple-negative breast cancer (TNBC) and/or <i>BRCA</i> mutation-associated breast cancer.

Phase I: Veliparib with cisplatin (CP) and vinorelbine (VNR) in advanced triple-negative breast cancer (TNBC) and/or BRCA mutation-associated breast cancer.

Abstract Poster

Authors

null

Eve T. Rodler

Seattle Cancer Care Alliance, Seattle, WA

Eve T. Rodler , Julie Gralow , Brenda F. Kurland , Melissa Griffin , Rosa Yeh , John A. Thompson , Peggy Porter , Elizabeth M. Swisher , Vijayakrishna K. Gadi , Larissa A. Korde , Hannah M. Linden , Georgiana Kehr Ellis , Stacie Peacock Shepherd , Vincent L. Giranda , Xiaoyu Chai , Jeannette Hammond , Reina Hibbert , Bojana Askovich , Jennifer M. Specht

Sign-In to See More Abstracts, Journal Articles, Posters, Videos and Slides and to Bookmark Your Favorite Content.

Disclaimer

This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org

Poster Details

Meeting

2014 ASCO Annual Meeting

Session Type

Poster Session

Session Title

Developmental Therapeutics - Clinical Pharmacology and Experimental Therapeutics

Track

Developmental Therapeutics

Sub Track

Cytotoxic and Other Novel Agents

Clinical Trial Registration Number

NCT01104259

Citation

J Clin Oncol 32:5s, 2014 (suppl; abstr 2569)

DOI

10.1200/jco.2014.32.15_suppl.2569

Abstract #

2569

Poster Bd #

32

Abstract Disclosures

Similar Posters

First Author: George Somlo

First Author: Ecaterina Elena Dumbrava

First Author: Paolo Andrea Zucali

First Author: Shalu Pahuja